| Variable | Non-recovered | Recovered | p value |
|---|---|---|---|
| n=37 | n=22 | ||
| Age (years), mean (SD) | 27.9 (6.2) | 32.6 (7.0) | 0.014 |
| Black race, n (%) | 10 (37.0) | 3 (13.6) | 0.065 |
| Hypertension, n (%) | 10 (34.5) | 8 (36.4) | 0.889 |
| Preeclampsia, n (%) | 4 (13.8) | 7 (31.8) | 0.121 |
| Diabetes mellitus, n (%) | 7 (24.1) | 3 (13.6) | 0.350 |
| Autoimmune disorders, n (%) | 1 (3.4) | 0 (0.0) | 0.379 |
| Thyroid disease, n (%) | 3 (10.3) | 2 (9.1) | 0.881 |
| EF at Diagnosis, mean (SD) | 15.1 (11.7) | 23.5 (12.0) | 0.015 |
| EF at 6 months, mean (SD) | 24.9 (15.5) | 51.0 (16.2) | 0.000 |
| EF at 12 months, mean (SD) | 21.0 (13.8) | 55.0 (16.0) | 0.000 |
| Peak EF, mean (SD) | 32.0 (18.3) | 63.2 (3.4) | 0.000 |
| Final EF, mean (SD) | 21.7 (15.2) | 60.7 (4.8) | 0.000 |
| Major Adverse Event, n (%) | 27 (93.1) | 19 (86.4) | 0.423 |
| Deceased, n (%) | 10 (34.5) | 1 (4.5) | 0.010 |
| Months of Follow up, mean (SD) | 81.3 (58.7) | 91.0 (55.4) | 0.550 |
| Beta-blocker, n (%) | 27 (93.1) | 19 (86.4) | 0.423 |
| ACE-I/ARB, n (%) | 33 (89.0) | 20 (90.0) | 0.833 |
| Aldosterone Antagonist, n (%) | 23 (79.3) | 12 (54.5) | 0.059 |
| Diuretic, n (%) | 28 (96.6) | 18 (81.8) | 0.080 |
| Digoxin, n (%) | 21 (72.4) | 7 (31.8) | 0.004 |
| Bromocriptine, n (%) | 2 (6.9) | 0 (0.0) | 0.209 |